Mohamed H. Maher
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mohamed H. Maher has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Sinchita Roy-Chowdhuri
Department of Pathology The University of Texas MD Anderson Cancer Center Houston Texas USA
2 shared publications Srividya Arjuna
Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 shared publications- Anirban Maitra
Laura and Isaac Perlmutter Cancer Center, New York University Grossman School of Medicine, NYU Langone Health, New York City, New York, USA
1 shared publication Bieke Van Dorst
Biocartis NV, Mechelen, Belgium
1 shared publicationDoug Hebert
Biocartis NV, Mechelen, Belgium
1 shared publicationDzifa Duose
Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
1 shared publication
Latest Publications
- Open Access
- 19 June 2026
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 28 (9) , 702-711
Validation of NTRK Fusion Detection Using an Ultrarapid, Fully Automated Cartridge-Based PCR Assay
- 19 June 2026
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 28 (9) , 702-711
Open AccessValidation of NTRK Fusion Detection Using an Ultrarapid, Fully Automated Cartridge-Based PCR Assay
- 19 March 2025
- Published by Wiley in Cancer Cytopathology
- Vol. 133 (4) , e70008
An integrated multi‐omics biomarker approach using molecular profiling and microRNAs for evaluation of pancreatic cyst fluid
Background: Classification and risk stratification of pancreatic cysts are challenging because of limited radiographic and cytomorphologic features. Although molecular profiling has emerged as an ancillary test for pancreatic cyst fluid (PCF), additional high‐sensitivity and ‐specificity biomarkers are still needed for improved classification.Methods: In this study, PCF from 93 patients, including intraductal papillary mucinous neoplasms (n = 65), mucinous cystic neoplasms (n = 9), serous cystadenomas (n = 9), pancreatic cyst not otherwise specified (n = 8), and pseudocysts (n = 2), were evaluated for biomarkers. Molecular profiling by next‐generation sequencing was performed, and a subset of the cases (n = 32) were interrogated with 2083 microRNAs (miRNAs) to evaluate their use for pancreatic cyst risk stratification.Results: As independent PCF biomarkers in 32 cases with histologic diagnoses, three miRNAs performed significantly better than mutant KRAS, mutant GNAS, carcinoembryonic antigen (CEA), and serum carbohydrate antigen 19‐9 (CA19‐9) in discriminating high‐risk from low‐risk cysts. The three elevated miRNAs in combination with mutant KRAS, mutant GNAS, and serum CA19‐9 displayed similar diagnostic performance (miR‐4461: area under the curve [AUC], 0.950; 95% confidence interval [CI], 0.800–1; miR‐6723‐5p: AUC, 0.958; 95% CI, 0.850–1; miR‐6755‐3p: AUC, 0.942; 95% CI, 0.816–1) in discriminating high‐risk from low‐risk cysts, when compared to mutant KRAS, mutant GNAS, CEA, and serum CA19‐9 (AUC, 0.950; 95% CI, 0.825–1). In the absence of CA19‐9, the three‐marker panel of KRAS, GNAS, and miRNAs showed marginally improved performance compared with KRAS, GNAS, and CEA, which highlights the potential utility of miRNAs as biomarkers in PCF analysis.Conclusions: These findings demonstrate that a multiomics biomarker approach with elevated PCF miRNAs with mutant KRAS, mutant GNAS, and serum CA19‐9 may help in better detecting high‐risk cysts for early clinical intervention.
- 19 March 2025
- Published by Wiley in Cancer Cytopathology
- Vol. 133 (4) , e70008
An integrated multi‐omics biomarker approach using molecular profiling and microRNAs for evaluation of pancreatic cyst fluid
Background: Classification and risk stratification of pancreatic cysts are challenging because of limited radiographic and cytomorphologic features. Although molecular profiling has emerged as an ancillary test for pancreatic cyst fluid (PCF), additional high‐sensitivity and ‐specificity biomarkers are still needed for improved classification.Methods: In this study, PCF from 93 patients, including intraductal papillary mucinous neoplasms (n = 65), mucinous cystic neoplasms (n = 9), serous cystadenomas (n = 9), pancreatic cyst not otherwise specified (n = 8), and pseudocysts (n = 2), were evaluated for biomarkers. Molecular profiling by next‐generation sequencing was performed, and a subset of the cases (n = 32) were interrogated with 2083 microRNAs (miRNAs) to evaluate their use for pancreatic cyst risk stratification.Results: As independent PCF biomarkers in 32 cases with histologic diagnoses, three miRNAs performed significantly better than mutant KRAS, mutant GNAS, carcinoembryonic antigen (CEA), and serum carbohydrate antigen 19‐9 (CA19‐9) in discriminating high‐risk from low‐risk cysts. The three elevated miRNAs in combination with mutant KRAS, mutant GNAS, and serum CA19‐9 displayed similar diagnostic performance (miR‐4461: area under the curve [AUC], 0.950; 95% confidence interval [CI], 0.800–1; miR‐6723‐5p: AUC, 0.958; 95% CI, 0.850–1; miR‐6755‐3p: AUC, 0.942; 95% CI, 0.816–1) in discriminating high‐risk from low‐risk cysts, when compared to mutant KRAS, mutant GNAS, CEA, and serum CA19‐9 (AUC, 0.950; 95% CI, 0.825–1). In the absence of CA19‐9, the three‐marker panel of KRAS, GNAS, and miRNAs showed marginally improved performance compared with KRAS, GNAS, and CEA, which highlights the potential utility of miRNAs as biomarkers in PCF analysis.Conclusions: These findings demonstrate that a multiomics biomarker approach with elevated PCF miRNAs with mutant KRAS, mutant GNAS, and serum CA19‐9 may help in better detecting high‐risk cysts for early clinical intervention.
- 20 December 2024
- Published by Wiley in Cancer Cytopathology
- Vol. 133 (1) , e22925
A rapid turnaround time workflow for a cytological liquid biopsy assay using FNA supernatant specimens
Background: Genomic profiling is essential in the management of non–small cell lung cancer. However, this may often be challenging because of limited cytological tissue and extended turnaround time (TAT) for next‐generation sequencing (NGS). This study aims to describe a rapid TAT workflow for molecular profiling using fine‐needle aspiration (FNA) supernatants.Methods: A fully automated total nucleic acid extraction using the Genexus Integrated System was compared to a manual extraction using FNA supernatants from 50 patients with non–small cell lung cancer. Molecular profiling using the 50 gene Oncomine Precision Assay GX panel was performed and NGS results were compared with those of paired tissue samples.Results: The FNA samples processed using the automated Genexus purification system (n = 42) and the manual extraction method (n = 8) showed comparable quality control metrics with a median total nucleic acid yield of 1230 ng (18–17720 ng) and 1068 ng (777–1740 ng), respectively. The Genexus purification system reduced the hands‐on time from 120 to 30 minutes, enhancing workflow efficiency and decreasing the overall TAT. Of the 50 samples extracted, NGS was performed on 26 samples: seven via manual extraction and 19 using automated extraction. NGS quality control metrics were also comparable between both extraction methods. The overall TAT of the automated NGS workflow from specimen received to test result was 24 hours, providing rapid and reliable molecular results for timely clinical decision‐making and improved patient outcomes.
- 20 December 2024
- Published by Wiley in Cancer Cytopathology
- Vol. 133 (1) , e22925
A rapid turnaround time workflow for a cytological liquid biopsy assay using FNA supernatant specimens
Background: Genomic profiling is essential in the management of non–small cell lung cancer. However, this may often be challenging because of limited cytological tissue and extended turnaround time (TAT) for next‐generation sequencing (NGS). This study aims to describe a rapid TAT workflow for molecular profiling using fine‐needle aspiration (FNA) supernatants.Methods: A fully automated total nucleic acid extraction using the Genexus Integrated System was compared to a manual extraction using FNA supernatants from 50 patients with non–small cell lung cancer. Molecular profiling using the 50 gene Oncomine Precision Assay GX panel was performed and NGS results were compared with those of paired tissue samples.Results: The FNA samples processed using the automated Genexus purification system (n = 42) and the manual extraction method (n = 8) showed comparable quality control metrics with a median total nucleic acid yield of 1230 ng (18–17720 ng) and 1068 ng (777–1740 ng), respectively. The Genexus purification system reduced the hands‐on time from 120 to 30 minutes, enhancing workflow efficiency and decreasing the overall TAT. Of the 50 samples extracted, NGS was performed on 26 samples: seven via manual extraction and 19 using automated extraction. NGS quality control metrics were also comparable between both extraction methods. The overall TAT of the automated NGS workflow from specimen received to test result was 24 hours, providing rapid and reliable molecular results for timely clinical decision‐making and improved patient outcomes.
- Open Access
- 1 May 2020
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 13, 3903-3920
Dinutuximab Synergistically Enhances the Cytotoxicity of Natural Killer Cells to Retinoblastoma Through the Perforin-Granzyme B Pathway
Purpose: Conventional chemotherapy and enucleation usually fail to cure advanced retinoblastoma. We investigated the retinoblastoma immune microenvironment and the efficacy of the combination of dinutuximab and CD16-expressing NK-92MI (NK-92MIhCD16-GFP) cells on retinoblastoma cells in this study. Patients and Methods: Immunohistochemistry and flow cytometry (FC) were performed to assess the expression level of GD2 in retinoblastoma tissues and cells. Gene set enrichment analysis (GSEA), immunohistochemisrztry and immunocytochemistry were conducted to assess the retinoblastoma immune microenvironment and the integrity of the blood-retinal barrier (BRB). After overexpressing CD16 in NK-92MI cells, fluorescence-activated cell sorting (FACS) was applied to select the positive subpopulation. LDH assays and FC were used to detect LDH release and apoptosis in retinoblastoma cells subjected to a combination of dinutuximab and NK-92MIhCD16-GFP cells. Finally, the release of perforin-granzyme B and the expression of CD107a in NK-92MIhCD16-GFP stimulated by retinoblastoma cells were assessed via enzyme-linked immunosorbent assays (ELISAs) and FC in the presence of dinutuximab or an isotype control. Results: GD2 was heterogeneously expressed in retinoblastoma tissues and cell lines and positively correlated with proliferation and staging. GSEA revealed the immunosuppressive status of retinoblastoma microenvironment. The immune cell profile of retinoblastoma tissues and vitreous bodies suggested BRB destruction. LDH release and apoptosis in retinoblastoma cells caused by NK-92MIhCD16-GFP cells were significantly enhanced by dinutuximab. Finally, the release of perforin-granzyme B and the expression of CD107a in NK-92MIhCD16-GFP cells stimulated by retinoblastoma cells were obviously increased by dinutuximab. Conclusion: This study indicates that retinoblastoma impairs the integrity of the BRB and contributes to dysregulated immune cell infiltrates. GD2 is a specific target for natural killer (NK) cell-based immunotherapy and that the combination of dinutuximab and NK-92MIhCD16-GFP cells exerts potent antitumor effects through antibody-dependent cell-mediated cytotoxicity.
- 1 May 2020
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 13, 3903-3920
Open AccessDinutuximab Synergistically Enhances the Cytotoxicity of Natural Killer Cells to Retinoblastoma Through the Perforin-Granzyme B Pathway
Purpose: Conventional chemotherapy and enucleation usually fail to cure advanced retinoblastoma. We investigated the retinoblastoma immune microenvironment and the efficacy of the combination of dinutuximab and CD16-expressing NK-92MI (NK-92MIhCD16-GFP) cells on retinoblastoma cells in this study. Patients and Methods: Immunohistochemistry and flow cytometry (FC) were performed to assess the expression level of GD2 in retinoblastoma tissues and cells. Gene set enrichment analysis (GSEA), immunohistochemisrztry and immunocytochemistry were conducted to assess the retinoblastoma immune microenvironment and the integrity of the blood-retinal barrier (BRB). After overexpressing CD16 in NK-92MI cells, fluorescence-activated cell sorting (FACS) was applied to select the positive subpopulation. LDH assays and FC were used to detect LDH release and apoptosis in retinoblastoma cells subjected to a combination of dinutuximab and NK-92MIhCD16-GFP cells. Finally, the release of perforin-granzyme B and the expression of CD107a in NK-92MIhCD16-GFP stimulated by retinoblastoma cells were assessed via enzyme-linked immunosorbent assays (ELISAs) and FC in the presence of dinutuximab or an isotype control. Results: GD2 was heterogeneously expressed in retinoblastoma tissues and cell lines and positively correlated with proliferation and staging. GSEA revealed the immunosuppressive status of retinoblastoma microenvironment. The immune cell profile of retinoblastoma tissues and vitreous bodies suggested BRB destruction. LDH release and apoptosis in retinoblastoma cells caused by NK-92MIhCD16-GFP cells were significantly enhanced by dinutuximab. Finally, the release of perforin-granzyme B and the expression of CD107a in NK-92MIhCD16-GFP cells stimulated by retinoblastoma cells were obviously increased by dinutuximab. Conclusion: This study indicates that retinoblastoma impairs the integrity of the BRB and contributes to dysregulated immune cell infiltrates. GD2 is a specific target for natural killer (NK) cell-based immunotherapy and that the combination of dinutuximab and NK-92MIhCD16-GFP cells exerts potent antitumor effects through antibody-dependent cell-mediated cytotoxicity.